Predictive Oncology (NASDAQ: POAI) CEO Dr. Carl
Schwartz recently referred to the company’s Helomics subsidiary as a “major
asset” during an exclusive NNW interview with Stuart Smith (http://ibn.fm/8knZX). An article
discussing the interview reads, “During the interview, Schwartz pointed out
that Helomics’ collection of more than 150,000 cancer tumors is the largest
inventory of its kind in the world and that the impressive collection ‘was
amassed over the last two decades by physicians sending in cancerous tumors to
be tested with the known therapies of the time. The results of these tests were
in turn sent back to the referring physicians to be used as a guide or a
reference as desired for treatment of the evaluated tumor,’ he continued. ‘And the
evaluated tumor was placed back in the physician’s therapy inventory. That’s
how we amassed all these tumors.’ . . . Schwartz explained that POAI was intent
on proving that it can sequence, ‘which is genetically profile our tumors, and
do what is called a ‘reach back,’ or examination of what eventually happened to
these patients over an extended period of time. I want to strongly emphasize
that Helomics is the only company with the ability to do this ‘reach back’ at
this time because only we have a patient history.’”
To view the full article, visit http://ibn.fm/ZoNgh
About Predictive Oncology Inc.
Predictive Oncology operates through three segments
(domestic, international and other) that contain four subsidiaries; Helomics,
TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial
intelligence to its rich data gathered from patient tumors to both personalize
cancer therapies for patients and drive the development of new targeted therapies
in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab
provides clinical testing that assists oncologists in individualizing
patient-treatment decisions by providing an evidence-based road map for
therapy. In addition to its proprietary precision oncology platform, Helomics
offers boutique CRO services that leverage its TruTumor(TM), patient-derived
tumor models coupled with a wide range of multi-omics assays (genomics,
proteomics and biochemical), and an AI-powered proprietary bioinformatics
platform to provide a tailored solution to its clients’ specific needs.
Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid
approach to growing tumors in the laboratory, which essentially “fools” cancer
cells into thinking they are still growing inside a patient. Its proprietary
Oncology Discovery Technology Platform Kits will assist researchers and
clinicians to identify which cancer cells bind to specific biomarkers. Once the
biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture
Technology Platforms, which isolate and help categorize an individual patient’s
heterogeneous tumor samples to enable the development of patient-specific
treatment options. Helomics and TumorGenesis are focused on ovarian cancer.
Predictive Oncology’s Skyline Medical division markets its patented and
FDA-cleared STREAMWAY System, which automates the collection, measurement and
disposal of waste fluid, including blood, irrigation fluid and others, within a
medical facility, through both domestic and international divisions. The
company has achieved sales in five of the seven continents through both direct
sales and distributor partners. For more information, visit the company’s
website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
